摘要
为探讨新型生物标本口腔液在新型冠状病毒(SARS-CoV-2)核酸和抗体检测中的应用价值,采集2021年10—11月北京两起新型冠状病毒肺炎(简称“新冠肺炎”)聚集性疫情的7例确诊病例的口腔液及配对的呼吸道和血液样本。采用荧光定量PCR和血清抗体检测试剂盒分别检测SARS-CoV-2核酸和IgG抗体,同时采用新建的磁微粒化学发光法检测口腔液标本SARS-CoV-2 IgG抗体。结果显示,3例新冠肺炎确诊病例鼻咽拭子、咽拭子和口腔液标本SARS-CoV-2核酸检测结果均为阳性,其中2例病例口腔液双基因循环阈值(Ct值)与咽拭子相近,1例高于咽拭子。获得1例确诊病例口腔液标本全基因组序列,属于VOC/Delta变异株。口腔液和配对血清标本SARS-CoV-2 IgG抗体均为阳性,口腔液的S/CO值较血清低。其中,采集到口腔液系列标本的病例,口腔液抗体水平在发病后11~32 d呈上升趋势。
This study aimed to explore the application value of new biological specimen oral fluid in SARS-CoV-2 nucleic acid and antibody detection.Oral fluid and paired respiratory and blood specimens from 7 confirmed cases of two COVID-19 cluster epidemic were collected in Beijing from October to November 2021.SARS-CoV-2 virus and IgG antibody were detected by real time PCR kits and serum antibody detection reagents,and SARS-CoV-2 IgG antibody in oral fluids was detected by a new established method of magnetic particle chemiluminescence.The results showed that the nucleic acid amplification test of SARS-CoV-2 on nasopharyngeal swabs,throat swabs and oral fluid specimens from 3 confirmed cases of COVID-19 was positive,among which the Ct value for ORF1a/b and N gene of oral fluid samples in 2 cases was close to that of throat swab,and the Ct value of oral fluid sample for 1 case was higher than that of throat swab.The complete genome sequence of one oral fluid specimen was obtained,which belonged to the VOC/Delta variant strain.The SARS-CoV-2 IgG antibodies of the paired oral fluid and serum were all positive,and the S/CO values of oral fluid were all lower than those of serum.The series of oral fluid results showed that SARS-CoV-2 IgG antibody level increased from 11 to 32 days after the onset of the disease.
作者
黄琪
刘方遥
毛乃颖
孙静怡
董梅
谢会
刘锋
张恒
于霞丽
董建平
许文波
黄芳
Huang Qi;Liu Fangyao;Mao Naiying;Sun Jingyi;Dong Mei;Xie Hui;Liu Feng;Zhang Heng;Yu Xiali;Dong Jianping;Xu Wenbo;Huang Fang(School of Public Health,Capital Medical University,Beijing 100069,China;Institute of Preventive Immunization,Beijing Center for Disease Control and Prevention/Beijing Academy for Preventive Medicine/Beijing Institute of Tuberculosis Control Research and Prevention,Beijing 100013,China;Department of Microbiology Laboratory,Beijing Haidian Center for Disease Control and Prevention,Beijing 100094,China;Institute for Viral Disease Control and Prevention,Chinese Centers for Disease control and Prevention,Beijing 102206,China;NHC Key Laboratory for Medical Virology and Viral Diseases,Beijing 102206,China;Department Infectious Disease,Beijing Haidian Hospital,Beijing 100080,China)
出处
《中华预防医学杂志》
CAS
CSCD
北大核心
2022年第3期355-359,共5页
Chinese Journal of Preventive Medicine
基金
首都卫生发展科研专项(2021-1G-3011)
首都卫生发展科研专项(2021-1G-3015)。
